$EVAX News

EVAX Stock Heads For Best Week Since January 2025 As Cancer Vaccine Shows 89% Target Precision

Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion Reports All Patients Maintained Clinical Response With No Tumor Progression Through Year Three Of EVX-01 Monotherapy In Advanced Melanoma Phase 2 Trial, 89% Of Vaccine Neoantigens Triggered T-Cell Responses

Evaxion stock surges on 3-year melanoma vaccine trial data

Evaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01

Evaxion will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting

Evaxion applies its AI-Immunology™ platform in autoimmune diseases

Evaxion AS (EVAX) (Q2 2026) Earnings Call Highlights: Strong EVX-01 Data and Field Validation ...

Can Merck & Company (MRK)’s Stake in Evaxion A/S (EVAX) Validate the Potential of AI-Driven Vaccine Discovery?

Evaxion A/S 2026 Q2 - Results - Earnings Call Presentation

Evaxion A/S (EVAX) Q2 2026 Earnings Call Transcript

Evaxion announces business update and second quarter 2026 financial results

Evaxion Biotech Q2 2026 Earnings Call: Complete Transcript

Evaxion Biotech Q2 EPS $(0.01) Beats $(0.31) Estimate

Evaxion expands and refocuses R&D pipeline with EVX-05, an AI-designed off-the-shelf brain cancer vaccine program

Evaxion Expands Pipeline Of Cancer Vaccine Programs With EVX-05 Against Deadly Brain Cancer Glioblastoma

Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026

Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026

Evaxion To Present 3-Yr Clinical Efficacy Data From Phase 2 Trial With Personalized Cancer Vaccine Candidate EVX-01 At ESMO Congress 2026

Reported Sunday, Evaxion Presents New Preclinical Data Showing Multi-Component EVX-V1 Vaccine Pairs AI-Discovered Antigens With AI-Optimized Antigens To Target CMV From Multiple Angles